Key Highlights
- Marvel Biosciences awarded 59,693 deferred share units to three independent directors instead of cash fees.
- The deferred share units vest on November 18, 2027 and are settled when a director leaves the company.
- The units were valued using a $0.13 volume-weighted average share price on November 17, 2026.
Marvel Biosciences Corp. (TSXV: MRVL) has awarded 59,693 deferred share units to its three independent directors in place of cash payment for directors’ fees, according to a company press release.
The company said the deferred share units (DSUs) will all vest on November 18, 2027. Once vested, the DSUs are to be settled when a director separates from service from the company, and the DSUs expire 365 days after that separation.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Marvel said the deemed value of the DSUs was calculated using the volume-weighted average price of its common shares on the TSX Venture Exchange on November 17, 2026, which it reported as $0.13, multiplied by the number of DSUs awarded.
Marvel Biosciences, through its wholly owned subsidiary Marvel Biotechnology Inc., describes itself as a Calgary-based pre-clinical stage biotechnology company developing MB-204, a fluorinated derivative of the anti-Parkinson’s drug istradefylline.
Read the original press release on Stockhouse.com.
s-17v5_h-18v5_i-19v5